MYC is a Critical Target of FBXW7
Overview
Affiliations
MYC deregulation is a driver of many human cancers. Altering the balance of MYC protein levels at the level of transcription, protein stability, or turnover is sufficient to transform cells to a tumorigenic phenotype. While direct targeting of MYC is difficult, specific genetic vulnerabilities of MYC-deregulated cells could be exploited to selectively inhibit their growth. Using a genome-wide shRNA screen, we identified 78 candidate genes, which are required for survival of human mammary epithelial cells with elevated MYC levels. Among the candidates, we validated and characterized FBXW7, a component of the SCF-like ubiquitin ligase complex that targets MYC for proteasomal degradation. Down-regulation of FBXW7 leads to synergistic accumulation of cellular and active chromatin-bound MYC, while protein levels of other FBXW7 targets appear unaffected. Over a four-week time course, continuous FBXW7 down-regulation and MYC activation together cause an accumulation of cells in S-phase and G2/M-phase of the cell cycle. Under these conditions, we also observe elevated chromatin-bound levels of CDC45, suggesting increased DNA replication stress. Consistent with these results, FBXW7 down-regulation alone decreases the survival of T47D breast cancer cells. These results establish that FBXW7 down-regulation is synthetic lethal with MYC, and that MYC is a critical target of FBXW7 in breast epithelial cells.
Molecular and Pathological Features of Paediatric High-Grade Gliomas.
Blasco-Santana L, Colmenero I Int J Mol Sci. 2024; 25(15).
PMID: 39126064 PMC: 11312892. DOI: 10.3390/ijms25158498.
Ulgen E, Gerlevik U, Gerlevik S, Oktay Y, Sezerman O, Turcan S Acta Neuropathol Commun. 2024; 12(1):95.
PMID: 38877600 PMC: 11177509. DOI: 10.1186/s40478-024-01811-1.
Lin P, Lourenco C, Cruickshank J, Palomero L, van Leeuwen J, Tong A Cancer Res. 2023; 83(24):4015-4029.
PMID: 37987734 PMC: 10722143. DOI: 10.1158/0008-5472.CAN-22-2948.
Inhibitors Targeting the F-BOX Proteins.
Naseem Y, Zhang C, Zhou X, Dong J, Xie J, Zhang H Cell Biochem Biophys. 2023; 81(4):577-597.
PMID: 37624574 DOI: 10.1007/s12013-023-01160-1.
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.
Seligson N, Tang J, Jin D, Bennett M, Elvin J, Graim K NPJ Precis Oncol. 2022; 6(1):29.
PMID: 35468996 PMC: 9038792. DOI: 10.1038/s41698-022-00271-x.